Introgen - eine mehr im Kampf gegen Krebs - 500 Beiträge pro Seite
eröffnet am 13.10.00 14:28:35 von
neuester Beitrag 05.06.01 16:40:25 von
neuester Beitrag 05.06.01 16:40:25 von
Beiträge: 9
ID: 269.237
ID: 269.237
Aufrufe heute: 0
Gesamt: 408
Gesamt: 408
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| 20.04.24, 12:11 | 167 | |
| heute 00:14 | 161 | |
| 05.12.14, 17:15 | 155 | |
| heute 00:04 | 123 | |
| 23.10.15, 12:38 | 116 | |
| gestern 09:54 | 103 | |
| gestern 21:21 | 92 | |
| 06.03.17, 11:10 | 75 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.161,01 | +1,36 | 217 | |||
| 2. | 3. | 0,1885 | -0,26 | 90 | |||
| 3. | 2. | 1,1800 | -14,49 | 77 | |||
| 4. | 5. | 9,3500 | +1,14 | 60 | |||
| 5. | 4. | 168,29 | -1,11 | 50 | |||
| 6. | Neu! | 0,4400 | +3,53 | 36 | |||
| 7. | Neu! | 4,7950 | +6,91 | 34 | |||
| 8. | Neu! | 11,905 | +14,97 | 31 |
Feedback
www.introgen.com
Seid gestern auf dem Markt - hat wohl bei der börsen lage alle Zeichnungsgewinne wieder abgegeben .
Corporate Profile
Introgen is a leader in the development of gene therapy products to treat a variety of cancers. After becoming the first company to receive approval to treat cancer by direct introduction of a therapeutic gene inside the body (in vivo), Introgen has in-licensed genes, constructed viral and non-viral gene delivery systems, performed preclinical and clinical development and partnered two gene therapy product candidates with a major pharmaceutical company. With a successful track record of gene therapy product development, the Company has treated over 400 patients with more than 3,000 doses of its lead product candidate, INGN 201, in over 17 completed and ongoing Phase I and Phase II clinical trials worldwide. Introgen`s current and expected clinical trials evaluate the Company`s products both alone and in combination with chemotherapy, radiation and/or surgery. With the poor efficacy and debilitating side effects of current treatments, Introgen`s low-toxicity approach to cancer treatment has drawn global interest from oncologists.
Introgen also controls a broad intellectual property portfolio that includes more than 200 pending and issued patents for a variety of gene therapy technologies. The Company has active collaborations with numerous academic centers of excellence and pharmaceutical and biotechnology industry partners. In 1998, Introgen Therapeutics formed Gendux, a European subsidiary developing biopharmaceuticals.
Seid gestern auf dem Markt - hat wohl bei der börsen lage alle Zeichnungsgewinne wieder abgegeben .
Corporate Profile
Introgen is a leader in the development of gene therapy products to treat a variety of cancers. After becoming the first company to receive approval to treat cancer by direct introduction of a therapeutic gene inside the body (in vivo), Introgen has in-licensed genes, constructed viral and non-viral gene delivery systems, performed preclinical and clinical development and partnered two gene therapy product candidates with a major pharmaceutical company. With a successful track record of gene therapy product development, the Company has treated over 400 patients with more than 3,000 doses of its lead product candidate, INGN 201, in over 17 completed and ongoing Phase I and Phase II clinical trials worldwide. Introgen`s current and expected clinical trials evaluate the Company`s products both alone and in combination with chemotherapy, radiation and/or surgery. With the poor efficacy and debilitating side effects of current treatments, Introgen`s low-toxicity approach to cancer treatment has drawn global interest from oncologists.
Introgen also controls a broad intellectual property portfolio that includes more than 200 pending and issued patents for a variety of gene therapy technologies. The Company has active collaborations with numerous academic centers of excellence and pharmaceutical and biotechnology industry partners. In 1998, Introgen Therapeutics formed Gendux, a European subsidiary developing biopharmaceuticals.
INTROGEN THERAPEUTICS INC. SHARES DL -, 001 München 936231 10,00 +0,00 +0,00%
habe mich gerade hoch getastet bei 10 euro sind meine 250 euro angenommen worden lim 9,60 zuniedrig -
habe mich gerade hoch getastet bei 10 euro sind meine 250 euro angenommen worden lim 9,60 zuniedrig -
und schon 5000 euro umsatz ist doch was - ich hoffe wir haben glück
wenn einer noch ein paar info sausser homepage auftreiben dann immer rein damit
wenn einer noch ein paar info sausser homepage auftreiben dann immer rein damit
INTROGEN THERAPEUTICS INC. Nasdaq 46119F107 10,00 +1,50 +17,65%
sieht doch gut aus
sieht doch gut aus
Product Development
Product (Gene) Cancer
Indication Development
Status Commercial
Rights
INGN 201 (p53) Head & Neck Phase III Introgen/Aventis
Non-Small Cell Lung Phase II
Prostate Phase I
Bladder Phase I*
Ovarian Phase I*
Brain (glioblastoma) Phase I*
Bronchoalveolar Phase I*
Breast Phase I*
INGN 241 (mda-7) Various
(solid tumors) Preclinical Introgen
Breast Preclinical
Lung Preclinical
INGN 251 (PTEN)** Colorectal Preclinical Introgen
Brain (glioblastoma) Preclinical
INGN 231 (CCAM)** Prostate Preclinical Introgen
BAK Program Various Research Introgen
p16 Program Pancreatic Research Introgen
DBCCR1** Program Bladder Research Introgen
rsk3** Program Ovarian Research Introgen
Product (Gene) Cancer
Indication Development
Status Commercial
Rights
INGN 201 (p53) Head & Neck Phase III Introgen/Aventis
Non-Small Cell Lung Phase II
Prostate Phase I
Bladder Phase I*
Ovarian Phase I*
Brain (glioblastoma) Phase I*
Bronchoalveolar Phase I*
Breast Phase I*
INGN 241 (mda-7) Various
(solid tumors) Preclinical Introgen
Breast Preclinical
Lung Preclinical
INGN 251 (PTEN)** Colorectal Preclinical Introgen
Brain (glioblastoma) Preclinical
INGN 231 (CCAM)** Prostate Preclinical Introgen
BAK Program Various Research Introgen
p16 Program Pancreatic Research Introgen
DBCCR1** Program Bladder Research Introgen
rsk3** Program Ovarian Research Introgen
Trading Spotlight
INTROGEN THERAPEUTICS INC. SHARES DL -, 001 München 936231 14,40 +3,70 +34,58% und weiter gehts
Introgen Berlin 936231 17,20 +5,30 +44,54%
INTROGEN THERAPEUTICS INC. SHARES DL -, 001 Frankfurt 936231 7,35 -T +2,95 +67,05% 1.680,00 19:37/10.05.
INTROGEN THERAPEUTICS INC. SHARES DL -, 001 Berlin 936231 8,50 +1,88 +28,40%
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 215 | ||
| 90 | ||
| 78 | ||
| 58 | ||
| 55 | ||
| 35 | ||
| 34 | ||
| 29 | ||
| 27 | ||
| 25 |
| Wertpapier | Beiträge | |
|---|---|---|
| 21 | ||
| 19 | ||
| 19 | ||
| 19 | ||
| 18 | ||
| 17 | ||
| 17 | ||
| 16 | ||
| 15 | ||
| 14 |
